Navigation Links
diaDexus, Inc. Reports 2011 First Quarter Financial Results
Date:5/16/2011

isease and ischemic stroke associated with atherosclerosis. For more information, please visit the company's website at www.diaDexus.com.

Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products and other statements that are not historical in nature, particularly those that use terminology such as "will," "potential", "could," "can," "believe," "intends," "continue," "plans," "expects," "projects," "estimates" or comparable terminology. Forward-looking statements are based on current expectations and assumptions, and entail various known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to diaDexus that could cause actual results to differ materially from those expressed in such forward-looking statements include diaDexus' ability to maintain regulatory clearance for and successfully commercialize its PLAC Tests and new diagnostic products, including its enhanced PLAC TIA test; diaDexus' reliance on sole source third party manufacturers to manufacture and supply our main reagent and the PLAC Test; the company's relationships with key customers; the effects of government regulations and the company's ability to comply with such regulations; diaDexus' ability to demonstrate that treatment of individuals based on their Lp-PLA2 levels improves clinical outcomes in prospective clinical studies; the rate of adoption of the PLAC Test by doctors and laboratories; the third party payor's acceptance of and reimbursement for the PLAC Test; diaDexus' ability to retain key employees and to attract, retain and motivate other qualified personnel;
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
2. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015 BioElectronics Corporation (OTC ... Musculoskeletal Pain Therapy medical devices, announced today that ... ActiPatch 7-day trial device has been published in ... Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 ... submitted an assessment.  Chronic pain ...
(Date:8/4/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Animal Biotechnology - ... This report describes and evaluates animal ... pharmaceuticals as well as improvement in food production. ... application of biotechnology to manage genetic disorders and ...
(Date:8/4/2015)... Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX ),  a targeted oncology ... be presenting at the 2015 Wedbush PacGrow Healthcare Conference on ... PT) in New York . Charles ... will provide a corporate overview. A live audio ... page of Mirati,s corporate website at www.mirati.com . A ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... SPRING, Md., April 28, 2011 The U.S. ... acetate) in combination with prednisone (a steroid) to ... who have received prior docetaxel (chemotherapy). ... cancer, the male sex hormone testosterone stimulates prostate ...
... Sciences Inc. (PSI), a leading pharmaceutical CRO, and ... ethylene vinyl acetate (EVA) into pharmaceutical applications, are ... devices.  Building on years of collaboration, Particle Sciences ... provide Particle Sciences with preferred access to VitalDose™ ...
Cached Medicine Technology:FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 2Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 3
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, ... Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, ... lives," Dr. Carmona said. "I strongly believe in the mission of the company ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s ... for Nov. 3 – 4, 2015, at UC San Diego, will explore innovations ... improve food access, and manage resources efficiently against the dueling backdrop of a ...
(Date:8/4/2015)... Mount Horeb, WI (PRWEB) , ... August 04, 2015 , ... ... newly released video on the subject, Renew Man™ is standing up as a voice ... a 15-year veteran of the healthy aging industry with special experience and expertise in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... They say ... better understand certain health conditions, pictures and medical art can be essential. StayWell, a ... providers. , Krames Patient Education solutions have been used by physicians and other ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, ... entities, today announced that John Munro, a 15-year veteran of the eDiscovery services ... Services Operations. , “I am thrilled to join Discovia at this important point ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3
... U.S. News & World Report has ranked,Cincinnati Children,s ... United States in general pediatrics in the 2008 edition ... is,the highest Cincinnati Children,s has ever received from U.S. ... we owe a great debt of thanks,to the thousands ...
... WASHINGTON, May 30 The National Alliance on,Mental ... for her,contributions to public education about mental illness ... 2008., NAMI executive director Mike Fitzpatrick made ... in which he discussed the premiere of,two ...
... May 30 The following is being issued,by the Federation ... physician scientists from 58 countries across the globe, What: ... When: Wednesday, June 4-Monday, June 9, Where: Boston Marriott ... accelerate science that improves patient care, Wednesday, June 4, ...
... is Dec. 31, but FDA urges asthma patients to ... (HealthDay News) -- Asthma inhalers that contain the drug ... harm the ozone layer. And these inhalers won,t be ... urging patients to switch to alternative inhalers now. , ...
... hardest hit ... areas of the country, WILMINGTON, ... homeless after Cyclone Nargis swept through Myanmar. Malteser,International has been providing ... of Labutta in the Irrawaddy Delta. Present in,Myanmar since 2001, Malteser ...
... Indiana experienced a 50 percent membership ... growth since 2007, ... this 14-year-old, not-for-profit,Indiana managed health care plan -- surpassing the 300,000 mark ... 2007, the,company has also grown its employee base by 182 percent -- ...
Cached Medicine News:Health News:U.S. News Ranks Cincinnati Children's Among Top Three U.S. Children's Hospitals 2Health News:U.S. News Ranks Cincinnati Children's Among Top Three U.S. Children's Hospitals 3Health News:NAMI Blog: PBS, MTV and Jane Pauley 2Health News:World-Renowned Scientists to Lead Immunology Course 2Health News:World-Renowned Scientists to Lead Immunology Course 3Health News:World-Renowned Scientists to Lead Immunology Course 4Health News:Ozone-Depleting Inhalers Being Phased Out 2Health News:Ozone-Depleting Inhalers Being Phased Out 3Health News:More Than 78,000 are Dead and Millions are Homeless After Cyclone Nargis Swept Through Myanmar 2Health News:MDwise Enrollment Exceeds 300,000 Members 2
...
ENDOlap™ suction and irrigation trumpet valves...
... Clinicians are demanding smaller, higher ... their clinical and operational challenges. The ... a powerful architecture for superb High ... mobility and ease-of-use; and a versatile ...
... The Dimension Vista 1500 integrated ... nephelometry, IMT (integrated multisensor technology) ... design will integrate analysis of ... drugs-of-abuse, therapeutic drugs, immunosuppressive drugs, ...
Medicine Products: